Molecular and Structural Biology Program

12.0翻译后摘要：分子和结构生物学（MSB）计划 MSB计划是马里兰州马琳大学的一个高度创新的基础科学研究计划 和斯图尔特格林鲍姆综合癌症中心（UMGCCC），旨在为临床带来新的药物。 MSB成员在细胞和分子水平上研究与癌症相关的机制问题，并使用这些 这些发现有助于设计新的癌症治疗策略和候选药物。然后，这些代理商可以 用于临床项目（ET、HRC、TII）中的测试。MSB工作集中在三个方面：目标1，定义 癌症中基因组不稳定性的机制，研究由于DNA损伤导致的基因组不稳定性的来源 和/或癌症中DNA修复能力的丧失，并验证可行的治疗靶点以开发新的 利用这种基因组不稳定性治疗癌症的临床方法。目标2，确定变更 在癌症的基因表达和RNA功能，重点是治疗靶向翻译起始，RNA 生物学和被癌细胞吸收以驱动肿瘤生长的基因表达过程，和/或 转移目标3，定义癌症信号通路是如何失调的，试图了解如何 癌细胞信号传导可用于靶向癌细胞，包括开发抑制致癌的策略， 和/或癌症干细胞特异性途径和/或恢复肿瘤抑制功能。为了实现这些目标， MSB成员在其他UMGCCC项目中获得了广泛的专业知识， 研究结果的诊所，并通过特殊的共享服务的可用性。MSB的47名成员 该计划包括34名正式成员和13名准成员，他们进行以癌症为重点的研究， 960万美元的年度直接成本资金（总计1320万美元），包括来自NCI的120万美元（12.5%）和来自NCI的750万美元。 来自其他同行评审来源的百万美元。MSB成员每年从非同行评审的项目中获得83万美元 资金来源。在此资助期间，MSB成员撰写了455篇与癌症相关的出版物，其中 13%来自方案内，20%来自方案间，2%来自方案内和方案间 合作。很高比例的出版物（58%）是由外部研究人员撰写的，反映了 MSB计划的国家影响力，13%的出版物在影响因子≥10的期刊上发表。的MSB 该计划与其他UMGCCC研究计划合作，并参与社区外展， 参与作为一个桥梁，以确定癌症研究的优先事项，我们的社区在集水区。

12.0 Abstract: Molecular and Structural Biology (MSB) Program The MSB Program is a highly innovative basic science research program at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) that aims to bring new agents to the clinic. MSB members study mechanistic cancer-relevant questions at the cellular and molecular level and use these discoveries to design novel cancer therapeutic strategies and drug candidates. These agents are then available for testing in the clinical programs (ET, HRC, TII). MSB work is focused in three areas: Aim 1, Define mechanisms of genomic instability in cancer, investigates sources of genomic instability due to DNA damage and/or loss of DNA repair capabilities in cancer and validating actionable therapeutic targets to develop new clinical approaches that take advantage of such genomic instability for treating cancer. Aim 2, Identify changes in gene expression and RNA function in cancer, focuses on therapeutic targeting of translation initiation, RNA biology, and gene expression processes that are co-opted by cancer cells to drive tumor growth and/or metastasis. Aim 3, Define how signaling pathways in cancer are deregulated, seeks to understand how cancer cell signaling can be used to target cancer cells, including developing strategies to inhibit oncogenic and/or cancer stem cell-specific pathways and/or to restore tumor suppression functions. To achieve these aims, MSB members are supported by extensive expertise available in other UMGCCC programs in translating basic research findings to the clinic, and by availability of exceptional shared services. The 47 members of the MSB Program include 34 full members and 13 associate members who conduct cancer-focused research supported by $9.6 million annual direct cost funding ($13.2 million total), including $1.2 million (12.5%) from NCI and $7.5 million from other peer-reviewed sources. MSB members receive $0.83 million annually from non–peer-reviewed funding sources. During this funding period, MSB members authored 455 cancer-related publications, of which 13% resulted from intraprogrammatic, 20% from interprogrammatic, and 2% from intra and interprogrammatic collaborations. A high percentage of publications (58%) are with external investigators, reflecting the high national impact of the MSB Program and 13% of publications are in journals with an impact factor ≥10. The MSB Program collaborates with other UMGCCC research programs and engages Community Outreach and Engagement as a bridge to identify cancer research priorities of our community in the catchment area.